AVT 01

Drug Profile

AVT 01

Alternative Names: AVT-01; AVT-01 decoy ODN; AVT-01 decoy oligodeoxynucleotide

Latest Information Update: 23 Jan 2017

Price : $50

At a glance

  • Originator University of Gottingen
  • Developer DOLTHERA
  • Class Anti-inflammatories; Antiasthmatics; Oligonucleotides
  • Mechanism of Action STAT1 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 13 Mar 2014 Activaero GmbH has been acquired by Vectura
  • 22 Jan 2008 AVT 01 is still in phase IIa trials for asthma in the UK and Romania
  • 13 Nov 2006 Phase-II clinical trials in Asthma in Romania (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top